Showing results (21-30 of 71) with videos related to
Sort By:
Pageof 8
The Prostate|November 26, 2009
Complex formation between human prostate-specific antigen and protease inhibitors in mouse plasmaCan Hekim, Tero Riipi, Lei Zhu, et al.Proceedings of the National Academy of Sciences of the United States of America|September 18, 2002
Nanocrystal targeting in vivoMaria E Akerman, Warren C W Chan, Pirjo Laakkonen, et al.Scandinavian Journal of Clinical and Laboratory Investigation|June 25, 2009
The role of glycodelin in cell differentiation and tumor growthHannu Koistinen, Laura C Hautala, Markku Seppälä, et al.Molecular Oncology|February 14, 2020
Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas, and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel wallsJohanna Eriksson, Vadim Le Joncour, Tiina Jahkola, et al.Cancer Letters|January 7, 2020
ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancerMark Barok, Vadim Le Joncour, Ana Martins, et al.International Journal of Cancer|August 23, 2008
Glycodelin reduces breast cancer xenograft growth in vivoLaura C Hautala, Riitta Koistinen, Markku Seppälä, et al.The Journal of Gene Medicine|July 26, 2008
Tumor targeting of baculovirus displaying a lymphatic homing peptideAnna R Mäkelä, Juulia Enbäck, Johanna P Laakkonen, et al.ACS Omega|June 29, 2026
Exclusively Chemoselective <i>S</i>‑Acylation for Peptide Radiolabeling Using [<sup>18</sup>F]Fluoronicotinic Acid 4‑Nitrophenyl Ester as a Prosthetic CompoundNelson Nwaenie, Tuomas Karskela, Pyry Dillemuth, et al.The Journal of Clinical Investigation|March 17, 2007
Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomasGrzegorz Sarek, Sari Kurki, Juulia Enbäck, et al.Oncotarget|February 27, 2016
Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progressionJohanna Eriksson, Vadim Le Joncour, Pirjo Nummela, et al.Pageof 8